Clinically relevant model of oxaliplatin-induced sinusoidal obstruction syndrome.
colorectal liver metastasis
liver sinusoidal endothelial cell
matrix metalloproteinase 9
micro-minipig
oxaliplatin
sinusoidal obstruction syndrome
Journal
Hepatology research : the official journal of the Japan Society of Hepatology
ISSN: 1386-6346
Titre abrégé: Hepatol Res
Pays: Netherlands
ID NLM: 9711801
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
revised:
12
09
2022
received:
26
08
2022
accepted:
15
09
2022
pubmed:
24
9
2022
medline:
24
9
2022
entrez:
23
9
2022
Statut:
ppublish
Résumé
Sinusoidal obstruction syndrome (SOS) induced by oxaliplatin-including chemotherapies (OXCx) is associated with impaired hepatic reserve and higher morbidity after hepatic resection. However, in the absence of an appropriate animal experimental model, little is known about its pathophysiology. This study aimed to establish a clinically relevant reproducible model of FOLFOX-induced SOS and to compare the clinical/histopathological features between the clinical and animal SOS settings. We performed clinical/pathological analyses of colorectal liver metastasis (CRLM) patients who underwent hepatectomy with/without preoperative treatment of FOLFOX (n = 22/18). Male micro-minipigs were treated with 50% of the standard human dosage of the FOLFOX regimen. In contrast to the monocrotaline-induced SOS model in rats, hepatomegaly, ascites, congestion, and coagulative necrosis of hepatocytes were absent in patients with CRLM with OXCx pretreatment and OXCx-treated micro-minipigs. In parallel to CRLM cases with OXCx pretreatment, OXCx-challenged micro-minipigs exhibited deteriorated indocyanine green clearance, morphological alteration of liver sinusoidal endothelial cells, and upregulated matrix metalloproteinase-9. Using our novel porcine SOS model, we identified the hepatoprotective influence of recombinant human soluble thrombomodulin in OXCx-SOS. With distinct differences between monocrotaline-induced rat SOS and human/pig OXCx-SOS, our pig OXCx-SOS model serves as a preclinical platform for future investigations to dissect the pathophysiology of OXCx-SOS and seek preventive strategies.
Types de publication
Journal Article
Langues
eng
Pagination
145-159Subventions
Organisme : Japan Society for the Promotion of Science
ID : 16H05414
Organisme : Japan Society for the Promotion of Science
ID : 18K08645
Organisme : Japan Society for the Promotion of Science
ID : 19K24012
Informations de copyright
© 2022 Japan Society of Hepatology.
Références
Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg. 1990;77(11):1241-6. https://doi.org/10.1002/bjs.1800771115
Okuno M, Hatano E, Toda R, Nishino H, Nakamura K, Ishii T, et al. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-RAS status for unresectable colorectal liver metastasis (BECK study): long-term results of survival. J Hepato-Biliary-Pancreatic Sci. 2020;27(8):496-509. https://doi.org/10.1002/jhbp.747
Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240(4):644-57. https://doi.org/10.1097/01.sla.0000141198.92114.f6
Hatano E, Okuno M, Nakamura K, Ishii T, Seo S, Taura K, et al. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study). J Hepato-Biliary-Pancreatic Sci. 2015;22(8):634-45. https://doi.org/10.1002/jhbp.254
Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15(3):460-6. https://doi.org/10.1093/annonc/mdh095
Nakano H, Oussoultzoglou E, Rosso E, Casnedi S, Chenard-Neu MP, Dufour P, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247(1):118-24. https://doi.org/10.1097/sla.0b013e31815774de
Soubrane O, Brouquet A, Zalinski S, Terris B, Brézault C, Mallet V, et al. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann Surg. 2010;251(3):454-60. https://doi.org/10.1097/sla.0b013e3181c79403
Tamandl D, Klinger M, Eipeldauer S, Herberger B, Kaczirek K, Gruenberger B, et al. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol. 2011;18(2):421-30. https://doi.org/10.1245/s10434-010-1317-4
Dignan FL, Wynn RF, Hadzic N, Karani J, Quaglia A, Pagliuca A, et al. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol. 2013;163(4):444-57. https://doi.org/10.1111/bjh.12558
DeLeve LD, McCuskey RS, Wang X, Hu L, McCuskey MK, Epstein RB, et al. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology. 1999;29(6):1779-91. https://doi.org/10.1002/hep.510290615
Narita M, Hatano E, Ikai I, Miyagawa-Hayashino A, Yanagida A, Nagata H, et al. A phosphodiesterase III inhibitor protects rat liver from sinusoidal obstruction syndrome through heme oxygenase-1 induction. Ann Surg. 2009;249(5):806-13. https://doi.org/10.1097/sla.0b013e3181a38ed5
Robinson SM, Mann J, Vasilaki A, Mathers J, Burt AD, Oakley F, et al. Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model. J Hepatol. 2013;59(2):318-26. https://doi.org/10.1016/j.jhep.2013.04.014
Robinson SM, Mann DA, Manas DM, Oakley F, Mann J, White SA. The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome. Br J Cancer. 2013;109(9):2396-403. https://doi.org/10.1038/bjc.2013.604
Park SH, Lee SS, Sung JY, Na K, Kim HJ, Kim SY, et al. Noninvasive assessment of hepatic sinusoidal obstructive syndrome using acoustic radiation force impulse elastography imaging: a proof-of-concept study in rat models. Eur Radiol. 2018;28(5):2096-106. https://doi.org/10.1007/s00330-017-5179-z
Hubert C, Dahrenmoller C, Marique L, Jabbour N, Gianello P, Leclercq I. Hepatic regeneration in a rat model is impaired by chemotherapy agents used in metastatic colorectal cancer. Eur J Surg Oncol. 2015;41(11):1471-8. https://doi.org/10.1016/j.ejso.2015.08.152
Lentschener C, Nicco C, Terris B, Samama CM, Coriat R. Comment on ‘The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome’. Br J Cancer. 2016;115(8):e7. https://doi.org/10.1038/bjc.2016.242
Robinson SM, Mann DA, Manas DM, Oakley F, Mann J, White SA. Response to ‘Comment on ‘The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome”. Br J Cancer. 2016;115(8):e8. https://doi.org/10.1038/bjc.2016.268
Nakamura K, Hatano E, Miyagawa-Hayashino A, Okuno M, Koyama Y, Narita M, et al. Soluble thrombomodulin attenuates sinusoidal obstruction syndrome in rat through suppression of high mobility group box 1. Liver Int. 2014;34(10):1473-87. https://doi.org/10.1111/liv.12420
Takada S, Miyashita T, Yamamoto Y, Kanou S, Munesue S, Ohbatake Y, et al. Soluble thrombomodulin attenuates endothelial cell damage in hepatic sinusoidal obstruction syndrome. In Vivo. 2018;32(6):1409-17. https://doi.org/10.21873/invivo.11393
Guglielmelli T, Bringhen S, Palumbo A. Update on the use of defibrotide. Expet Opin Biol Ther. 2012;12(3):353-61. https://doi.org/10.1517/14712598.2012.657623
Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127(13):1656-65. https://doi.org/10.1182/blood-2015-10-676924
Corbacioglu S, Carreras E, Mohty M, Pagliuca A, Boelens JJ, Damaj G, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: final results from the international compassionate-use program. Biol Blood Marrow Transplant. 2016;22(10):1874-82. https://doi.org/10.1016/j.bbmt.2016.07.001
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205-13. https://doi.org/10.1097/01.sla.0000133083.54934.ae
Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, et al. Posthepatectomy liver failure: a definition and grading by the international study group of liver surgery (ISGLS). Surgery. 2011;149(5):713-24. https://doi.org/10.1016/j.surg.2010.10.001
Kucybała I, Ciuk S, Tęczar J. Spleen enlargement assessment using computed tomography: which coefficient correlates the strongest with the real volume of the spleen? Abdom Radiol. 2018;43(9):2455-61. https://doi.org/10.1007/s00261-018-1500-9
Nakamura K, Hatano E, Narita M, Miyagawa-Hayashino A, Koyama Y, Nagata H, et al. Sorafenib attenuates monocrotaline-induced sinusoidal obstruction syndrome in rats through suppression of JNK and MMP-9. J Hepatol. 2012;57(5):1037-43. https://doi.org/10.1016/j.jhep.2012.07.004
Deleve LD, Wang X, Tsai J, Kanel G, Strasberg S, Tokes ZA. Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition. Gastroenterology. 2003;125(3):882-90. https://doi.org/10.1016/s0016-5085(03)01056-4
Okuno M, Hatano E, Nakamura K, Miyagawa-Hayashino A, Kasai Y, Nishio T, et al. Regorafenib suppresses sinusoidal obstruction syndrome in rats. J Surg Res. 2015;193(2):693-703. https://doi.org/10.1016/j.jss.2014.08.052
Narita M, Oussoultzoglou E, Chenard M-P, Fuchshuber P, Rather M, Rosso E, et al. Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization. Ann Surg Oncol. 2012;19(7):2230-7. https://doi.org/10.1245/s10434-011-2112-6
U.S. Food and Drug Administration. Highlights of prescribing information: eloxatin (oxaliplatin) injection, for intravenous use. Initial U.S. Approval: 2002. 2002. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021759s023lbl.pdf
Shirao K. Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors. Jpn J Clin Oncol. 2006;36(5):295-300. https://doi.org/10.1093/jjco/hyl016
Oki E, Emi Y, Yamanaka T, Uetake H, Muro K, Takahashi T, et al. Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial). Br J Cancer. 2019;121(3):222-9. https://doi.org/10.1038/s41416-019-0518-2
Hubert C, Sempoux C, Humblet Y, Van Den Eynde M, Zech F, Leclercq I, et al. Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab. HPB. 2013;15(11):858-64. https://doi.org/10.1111/hpb.12047
Aloia T, Sebagh M, Plasse M, Karam V, Lévi F, Giacchetti S, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006;24(31):4983-90. https://doi.org/10.1200/jco.2006.05.8156
Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg. 2007;11(7):860-8. https://doi.org/10.1007/s11605-007-0149-4
Verma N, Rettenmeier AW, Schmitz-Spanke S. Recent advances in the use of Sus scrofa (pig) as a model system for proteomic studies. Proteomics. 2011;11(4):776-93. https://doi.org/10.1002/pmic.201000320
Park S, Kim HY, Kim H, Park JH, Kim JH, Kim KH, et al. Changes in noninvasive liver fibrosis indices and spleen size during chemotherapy: potential markers for oxaliplatin-induced sinusoidal obstruction syndrome. Medicine. 2016;95(2):e2454. https://doi.org/10.1097/md.0000000000002454
El Chediak A, Haydar AA, Hakim A, Massih SA, Hilal L, Mukherji D, et al. Increase in spleen volume as a predictor of oxaliplatin toxicity. Therapeut Clin Risk Manag. 2018;14:653-7. https://doi.org/10.2147/tcrm.s150968
Bando H, Yamada Y, Tanabe S, Nishikawa K, Gotoh M, Sugimoto N, et al. Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer. Gastric Cancer. 2016;19(3):919-26. https://doi.org/10.1007/s10120-015-0549-1
Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243:1-7. https://doi.org/10.1097/01.sla.0000193603.26265.c3
Takamoto T, Hashimoto T, Sano K, Maruyama Y, Inoue K, Ogata S, et al. Recovery of liver function after the cessation of preoperative chemotherapy for colorectal liver metastasis. Ann Surg Oncol. 2010;17(10):2747-55. https://doi.org/10.1245/s10434-010-1074-4
Nishino H, Okuno M, Seo S, Toda R, Yoshino K, Kasai Y, et al. Sinusoidal obstruction syndrome promotes liver metastatic seeding of colorectal cancer cells in a rat model. Anticancer Res. 2021;41(4):1803-10. https://doi.org/10.21873/anticanres.14946